201 related articles for article (PubMed ID: 34322853)
1. Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.
Castelnovo G; Gerlach O; Freedman MS; Bergmann A; Sinay V; Castillo-Triviño T; Kong G; Koster T; Williams H; Gafson AR; Killestein J
CNS Drugs; 2021 Sep; 35(9):1009-1022. PubMed ID: 34322853
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
3. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
5. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
6. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
Mitsikostas DD; Doskas T; Gkatzonis S; Fakas N; Maltezou M; Papadopoulos D; Gourgioti R; Mitsias P
Adv Ther; 2021 Mar; 38(3):1536-1551. PubMed ID: 33528792
[TBL] [Abstract][Full Text] [Related]
7. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study.
Bakirtzis C; Konstantinopoulou E; Langdon DW; Grigoriadou E; Minti F; Nikolaidis I; Boziki MK; Tatsi T; Ioannidis P; Karapanayiotides T; Afrantou T; Hadjigeorgiou G; Grigoriadis N
J Neurol Sci; 2018 Dec; 395():106-112. PubMed ID: 30308444
[TBL] [Abstract][Full Text] [Related]
9. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
10. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
11. Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial.
Pickering H; Murray J; Lin CS; Cormack C; Martin A; Kiernan MC; Krishnan AV
Clin Neurophysiol; 2017 Jan; 128(1):93-99. PubMed ID: 27871056
[TBL] [Abstract][Full Text] [Related]
12. Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.
Kim ES
Drugs; 2017 Sep; 77(14):1593-1602. PubMed ID: 28864863
[TBL] [Abstract][Full Text] [Related]
13. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
Rabadi MH; Kreymborg K; Vincent AS
Drugs R D; 2013 Sep; 13(3):175-81. PubMed ID: 23873597
[TBL] [Abstract][Full Text] [Related]
15. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
Coleman CI; Sobieraj DM; Marinucci LN
Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
19. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
[TBL] [Abstract][Full Text] [Related]
20. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
